In November 2001, the United States Food and Drug Administration (FDA) approved the first study aimed at developing ecstasy as a prescription treatment for post-traumatic stress disorder (PTSD). As of 2002, the researchers conducting the study, whose work was spearheaded by the Multidisciplinary Association for Psychedelic Studies (MAPS) were still awaiting approval from the university review board where the study is expected to take place. The investigators expect the feelings of trust and openness associated with ecstasy to help people who have experienced traumatic events work through their emotions and recover more quickly by reducing fear, depression, and anxiety. This is one of the first studies of its kind since ecstasy was placed on Schedule I by the Drug Enforcement Administration in1985. Schedule I drugs are illegal to possess, except in research performed under highly regulated conditions designed to protect patients. Other Schedule I...